Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
6.65
+0.13 (1.99%)
At close: Jun 12, 2026, 4:00 PM EDT
6.78
+0.13 (1.95%)
After-hours: Jun 12, 2026, 5:15 PM EDT
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,463,391
Market Cap
697.52M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -3 | -15.00% |
| Dec 31, 2023 | 20 | 6 | 42.86% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | -4 | -28.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Geron | 258 |
| CorMedix | 191 |
| Omeros | 175 |
| Allogene Therapeutics | 152 |
| Solid Biosciences | 121 |
| Aura Biosciences | 113 |
| CytomX Therapeutics | 69 |
RLMD News
- 1 day ago - Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program - GlobeNewsWire
- 3 days ago - Relmada Therapeutics Slides: Corporate presentation - Filings
- 8 days ago - Relmada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 15 days ago - Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 16 days ago - Relmada Therapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Relmada Therapeutics files automatic mixed securities shelf - TheFly
- 4 weeks ago - Relmada Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Relmada Therapeutics Quarterly report: Q1 2026 - Filings